Unichem laboratories has informed stock exchanges about a voluntary product recall by its US subsidiary under regulatory disclosure requirements. The pharmaceutical company's wholly-owned subsidiary, Unichem Pharmaceuticals (USA), Inc., has initiated a recall of specific products distributed in the United States market.

Product Recall Details

The recall involves Buspirone Hydrochloride Tablets that failed to meet quality specifications during routine stability testing. The company discovered out-of-specification assay results at the 12-month long-term stability time point, prompting the voluntary recall action.

Safety and Quality Assurance

Unichem Laboratories has confirmed that no adverse events related to this recall have been reported to date. The company emphasized its commitment to patient safety, stating that it places the highest priority on ensuring patient safety and maintaining product quality throughout every stage of its manufacturing and supply chain processes.

Regulatory Compliance

The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The communication was addressed to both the National Stock Exchange of India Limited and BSE Limited on 12th April 2026, ensuring compliance with mandatory disclosure requirements for listed companies.

The voluntary nature of the recall demonstrates the company's proactive approach to quality control and regulatory compliance in international markets. Such recalls, while impacting operations, reflect pharmaceutical companies' adherence to stringent quality standards and patient safety protocols.

Unichem laboratories has received a credit rating reaffirmation from ICRA Limited, with the rating agency maintaining its [ICRA]A+ (Stable) rating for the pharmaceutical company's bank facilities totaling Rs. 180 crores. The company informed stock exchanges about this development through a regulatory filing under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Rating Details and Facility Breakdown

ICRA's Rating Committee has reaffirmed the credit rating across multiple facility categories for Unichem Laboratories. The rating action covers both fund-based and non-fund based banking facilities along with unallocated limits.

Banking Partner Distribution

The company maintains banking relationships with multiple financial institutions for its rated facilities. The distribution of bank limits shows a diversified approach to banking partnerships.

Rating Timeline and Communication

The original rating was assigned on March 31, 2026, and the reaffirmation was communicated through ICRA's letter dated April 09, 2026. K Srikumar, Senior Vice President and Co Group Head at ICRA, signed the rating communication addressed to Sanjay Jain, Chief Financial Officer of Unichem Laboratories.

Regulatory Compliance and Surveillance

The rating will become due for surveillance within one year from the date of the rating communication letter. ICRA has reserved the right to review and revise the rating based on new information, changes in circumstances, or any developments that could impact the company's debt servicing capability. The rating agency has emphasized that any changes in terms, conditions, or size of the rated instruments would require a review of the ratings.